Longeveron Inc (LGVN)

11:54 AM

What risks could impact Longeveron Inc. stock performanceMarket-leading capital gains - jammulinksnews.com

11:54 AM

Jul 23, 2025

Longeveron Inc. Stock Analysis and ForecastFree Wealth Management Insights - Autocar Professional

Jul 23, 2025

Jul 23, 2025

Is Longeveron Inc. a good long term investmentExplosive earnings growth - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

How Longeveron Inc. stock performs during market volatilityIntraday Trade Ideas - Newser

Jul 22, 2025

Jul 22, 2025

What drives Longeveron Inc. stock priceHigh-impact investment strategies - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

What analysts say about Longeveron Inc. stockTriple-digit wealth increases - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

Published on: 2025-07-22 07:30:15 - Autocar Professional

Jul 21, 2025

Jul 21, 2025

Longeveron licenses stem cell patent for heart disease treatment - Investing.com

Jul 21, 2025

Jul 21, 2025

Longeveron licenses stem cell patent for heart disease treatment By Investing.com - Investing.com Nigeria

Jul 21, 2025

Jul 21, 2025

Longeveron Licenses US Patent for Advanced Cardiomyogenic Cell Technology from University of Miami - Nasdaq

Jul 21, 2025

Jul 21, 2025

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease - The Manila Times

Jul 21, 2025

Jul 21, 2025

Revolutionary Heart Disease Breakthrough: Longeveron Licenses Safer Cardiac Stem Cell Technology - Stock Titan

Jul 21, 2025

Jul 16, 2025

What makes Longeveron Inc. stock price move sharplyFree Exclusive Stock Market Insights - Newser

Jul 16, 2025

Jul 15, 2025

Why Longeveron Inc. stock attracts strong analyst attentionLong Term Safe Yield Focus - Newser

Jul 15, 2025

Jul 09, 2025

Longeveron (LGVN) gets FDA nod to start Phase 2 laromestrocel trial | PLUG SEC FilingForm 424B7 - Stock Titan

Jul 09, 2025

Jul 09, 2025

Longeveron receives FDA approval for pediatric heart therapy IND By Investing.com - Investing.com South Africa

Jul 09, 2025

Jul 08, 2025

Longeveron®? Announces U.S. FDA Approval of IND Application for A Phase 2 Pivotal Registration Study Evaluating Laromestrocel as A Treatment of Pediatric Dilated Cardiomyopathy - MarketScreener

Jul 08, 2025

Jul 08, 2025

Longeveron® announces U.S. FDA approval of IND application - MarketScreener

Jul 08, 2025

Jul 08, 2025

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) - The Manila Times

Jul 08, 2025

Jul 08, 2025

Longeveron stock soars after FDA approves IND for heart failure treatment - Investing.com Nigeria

Jul 08, 2025

Jul 08, 2025

Longeveron stock soars after FDA approves IND for heart failure treatment By Investing.com - Investing.com South Africa

Jul 08, 2025

Jul 08, 2025

Longeveron Inc. Receives FDA Approval for IND Application to Advance Clinical Trial of Stem Cell Therapy for Pediatric Dilated Cardiomyopathy - Nasdaq

Jul 08, 2025

Jul 08, 2025

Breakthrough: FDA Fast-Tracks New Stem Cell Therapy for Fatal Children's Heart Condition - Stock Titan

Jul 08, 2025

Jul 02, 2025

Longeveron (NASDAQ:LGVN) Shares Down 1.5% – What’s Next? - Defense World

Jul 02, 2025

Jun 26, 2025

Longeveron appoints Than Powell as chief business officer - Investing.com

Jun 26, 2025

Jun 26, 2025

Longeveron (LGVN) Appoints New Chief Business Officer to Lead Strategic Initiatives | LGVN Stock News - GuruFocus

Jun 26, 2025

Jun 26, 2025

Longeveron® Appoints Than Powell as Chief Business Officer - GlobeNewswire

Jun 26, 2025

Jun 26, 2025

Longeveron appoints Than Powell as chief business officer By Investing.com - Investing.com Canada

Jun 26, 2025